News

InvestorsHub on MSN23h
Regeneron Shares Climb on Acquisition of 23andMe Assets in Bankruptcy Deal
Regeneron Pharmaceuticals (NASDAQ:REGN) saw its stock rise 2% after announcing it had secured a winning bid to acquire key ...
Regeneron to buy 23andMe for $256M in court-supervised sale
Regeneron Pharmaceuticals (NASDAQ:REGN) will buy substantially all assets of genetic testing firm 23andMe for a purchase pric ...
OraSure stock rises following Regeneron’s 23andMe acquisition
The market’s positive reaction to OraSure’s stock today reflects investor confidence in the company’s ongoing relationship with 23andMe under Regeneron’s ownership. The continuation of this ...
Nasdaq4d
Regeneron Pharmaceuticals Celebrates Jury Verdict Against Amgen for Antitrust Violations, Awarding $406.8 Million in Damages
In children aged 8 to 11 years, PRALUENT should be given by a caregiver. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming ...
Regeneron wins over $400M jury award as Amgen found liable in antitrust case
A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...
Regeneron stock rises on 23andMe assets acquisition
The planned purchase will allow Regeneron to integrate 23andMe’s extensive genetic data into its research efforts, potentially leading to new medical advancements. Regeneron has stated its commitment ...
Nasdaq5d
Beyond The Numbers: 16 Analysts Discuss Regeneron Pharmaceuticals Stock
Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...
Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down
Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...
Mason Hawkins' Strategic Move: Regeneron Pharmaceuticals Inc. Takes Center Stage
The most significant addition was Regeneron Pharmaceuticals Inc (NASDAQ:REGN), with 114,880 shares, accounting for 3.88% of ...
Nasdaq6d
Citigroup Upgrades Regeneron Pharmaceuticals (LSE:0R2M)
There are 2,406 funds or institutions reporting positions in Regeneron Pharmaceuticals ... author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...